Skip to main content

Remote Job Finders (RJF)

OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
Scroll to top